Nasdaq GlobeNewswire

Bermuda Principles event merges science and business

Del

HAMILTON, Bermuda, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Scientists and researchers from around the world are gathering in Bermuda this week for the second edition of a conference exploring the field of genetic research.

Premier the Hon David Burt will officially open "Bermuda Principles: Impact on Splicing" Wednesday evening at the Fairmont Southampton. The conference, which runs through Saturday, has registered 50 delegates, along with an impressive roster of 36 speakers and panellists from 11 countries, including Australia, Denmark, Switzerland and South Africa.  Among the attendees are prominent geneticists, scientists, professors, researchers, PhD students working in international labs, biotech representatives and investors.

"I am elated to see the growth of the conference since last year's event," said Bermudian Dr. Carika Weldon, a biomedical researcher with her own lab at De Montfort University, UK, who conceived of the event and launched it last February. "My main aim has been to promote the Bermuda Principles document that was created at a conference that took place here back in 1996, and it's awesome to realise that thanks to the work we've done, more Bermudians, including our MPs, know about this now. It's an important legacy, and we should all be proud of the role Bermuda has played in genetics history."

In 1996, a scientific milestone occurred in Bermuda, after US and UK scientists met on the island to negotiate the completion of the Human Genome Project. In a landmark agreement, they decided gene sequences developed by numerous private labs would be made publicly available worldwide to advance scientific research. The agreement, called "The Bermuda Principles," contributed to the pace and reach of scientific research that followed.

This year's conference pays tribute to that history, while forging forward with a contemporary agenda of sessions dedicated to topics ranging from bioinformatics, regulation, technologies, therapeutics, gene splicing and disease, and commercialisation of university research. Speakers include keynote Adrian Krainer, Professor at Cold Spring Harbor Laboratory, New York; Jean Beggs, Fellow of the Royal Society and Professor, Edinburgh; Daniel Larson, of the Center for Cancer Research, Maryland; Franco Pagani, of the International Centre for Genetic Engineering and Biotechnology in Trieste, Italy; and Robin Reed, Professor of Cell Biology, Harvard Medical School.

One of the conference highlights will focus on how to commercialise scientific ideas, leveraging investment to turn them into viable businesses.

"As a researcher at a university, I had to quickly realise that what I was doing today could become a business venture tomorrow," said Weldon, who is also creating a foundation to promote science in the Bermuda community. "I have had to get my own head around commercialisation. In academia, we're taught to do experiments and publish, but sometimes that prevents you from turning an idea into a profitable venture. That's why I wanted to include this topic in the conference."

The closing session will feature the BDA's consultant for Emerging Technologies John Narraway and others discussing the island's attraction to biotech investors as a blue-chip international finance centre. It's one of numerous public-engagement events linking science to education, healthcare and business that will see conference participation by students, teachers, and medical and corporate professionals.

"Bermuda has long been the domicile for many established and well-known biotech companies," noted Narraway. "We see a conference like this as an opportunity to build a new ecosystem for early-stage biotech and life-science ventures. The BDA is participating in the event as a way to connect with these researchers and show the value the island can bring to those looking to transform their research into a commercial opportunity and licensable product."

Thursday night will feature a Bermuda Youth Parliament debate on the research use of immortal HeLa cells derived from a cancer patient. The event, to be live-streamed on Facebook, Twitter and Instagram, will be opened by Dr. Daniel Ford, Professor of Medicine at the Johns Hopkins University School of Medicine. Bermuda MPs have been invited to attend and winning students will receive smart phones courtesy of Digicel.

On Friday, local high-schoolers will carry out a genetic-engineering experiment using kits provided by Amino Labs in which colourful jellyfish DNA will be added to bacteria.

Saturday afternoon will see science teachers from local schools join doctors and other professionals for a panel discussion on integrating research into healthcare and education curricula.

The leading partner of the conference is Bank of Bermuda Foundation. Sponsors include: Bermuda Business Development Agency (BDA), Bermuda Technology Initiative, Bermuda Tourism Authority (BTA), De Montfort University, New England BioLabs, RNA Society, Island Press and Amino Labs.

MEDIA CONTACT:

Rosemary Jones
Head of Communications & Marketing
rosemary@bda.bm
441 278-6558
441 337-4696

CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business here smooth and beneficial.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0493acf0-aeec-4be0-88a2-3e42938c6112




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bermuda Business Development Agency (BDA) via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Manufacturing Leadership Forum Will Highlight Enabling Industry 4.0 with Analytics25.9.2018 15:06Pressemelding

Upcoming Dates in Houston, Texas and Antwerp, Belgium PORTLAND, Ore., Sept. 25, 2018 (GLOBE NEWSWIRE) -- New dates for The Manufacturing Leadership Forum were announced today including Houston, Texas, US on October 9, 2018 at the Petroleum Club of Houston and on November 28, 2018 in Antwerp, Belgium at the Lindner WTC Hotel & City Lounge. The events are sponsored by Northwest Analytics, a leading provider of manufacturing intelligence and SPC software solutions for manufacturers. This premier manufacturing analytics educational event focuses on enabling Industry 4.0 programs with manufacturing analytics. The Forums will feature keynotes and case-study presentations from globally-recognized leaders in the application of manufacturing analytics. In its fourth year, The Manufacturing Leadership Forum will open with a keynote from analytics visionary, Dr. Lloyd Colegrove, Director of Data Services & Fundamental Problem Solving at The Dow Chemical Company. “The Manufacturing Leadership Foru

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-10125.9.2018 14:00Pressemelding

Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019 NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 were presented yesterday in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer in Toronto. The oral presentation included further details on, and updates from, the dataset announced previously. CK-101 is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being evaluated in advanced non

SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test25.9.2018 14:00Pressemelding

Test supports international guidelines for treating antibiotic resistant STI SYDNEY, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not available for sale in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen or MG, along with genetic markers linked to antibiotic resistance. In recent years, Mgen prevalence has increased globally and developed high rates of resistance to the common antibiotic treatment, azithromycin. "This test is an exciting new development that will increase the precision of patient care for patients impacted by Mycoplasma genitalium - a common sexually transmitted infection with limited treatment options,” notes Dr Maria Trent, Professor of Pediatrics and Public Health at Johns Hopkins Medicine. The SpeeDx ResistancePlus MG test is in use in laboratories acr

Novavax Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults25.9.2018 13:00Pressemelding

First participants enrolled in Phase 2 clinical trial of quadrivalent NanoFlu formulations Top-line immunogenicity and safety data expected in the first quarter of 2019 Phase 2 results will support meeting with the U.S. Food and Drug Administration (FDA) and Phase 3 clinical trial design GAITHERSBURG, Md., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced the initiation of a Phase 2 dose and formulation confirmation clinical trial in older adults of NanoFlu, its nanoparticle seasonal influenza vaccine candidate. “Initiating this Phase 2 clinical trial of NanoFlu is an important milestone for Novavax,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “With top-line results expected in the first quarter of 2019, we plan to discuss these data with the FDA at an ‘End of Phase 2’ meeting and to agree on the appropriate Phase 3 clinical trial design to support licensure via accelerated approval. We continue to believe NanoFlu is a differen

CGAP Launches Photo and Video Contest Theme for 2018: Financial Inclusion in Africa25.9.2018 13:00Pressemelding

This year's CGAP contest is the first ever to accept short video entries WASHINGTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- The Consultative Group to Assist the Poor’s (CGAP) 13th annual photo contest, launched today, is seeking striking images on financial inclusion in Africa. For the first time, short video submissions on Africa also will be accepted. Entries may be submitted through December 14, 2018. Each contestant may submit up to 20 photos or videos to compete for the Grand Prize worth US$ 2,000. This year CGAP is looking for original and compelling photographs and short videos that tell the story of how financial services empower poor people and communities in Africa. The region is a center for financial innovation -- home to M-Pesa, the mobile money service launched a decade ago now replicated across markets worldwide; host to vibrant FinTech and e-commerce companies; and to a growing off-grid sector that leverages digital finance. Together these innovators contribute toward lifti

Kick-starting health in the workplace25.9.2018 10:00Pressemelding

Over 800 organizations step, bike, swim and yoga their way to better health and wellbeing as the May 2018 Virgin Pulse Global Challenge Concludes ZURICH, Switzerland, Sept. 25, 2018 (GLOBE NEWSWIRE) -- On August 30th more than 270,000 people, across 144 countries, completed Virgin Pulse’s 100-day Global Challenge, moving them towards a more active, healthy and productive lifestyle. With this achievement, Virgin Pulse, an international leader in employee health and wellbeing, once again proves it’s helping to improve employee lives for good. The company’s Global Challenge event encourages exercise, mindfulness and healthy habits at work, leading to a happier culture and reduced costs to the organization. “Through increased awareness, education and motivation, employees master long-term, sustainable habits allowing them to arrive at work feeling more engaged, productive and equipped for peak performance,” says David Osborne, Chief Executive Officer of Virgin Pulse. “The follow-on effects

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom